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A novel panel of differentially-
expressed microRNAs in breast 
cancer brain metastasis may predict 
patient survival
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Philip S. Rudland3, Michael D. Jenkinson4,7, Leonie S. Young5, Francesco Falciani2 & 
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Breast cancer brain metastasis (BCBM) is an area of unmet clinical need. MicroRNAs (miRNAs) 
have been linked to the metastatic process in breast cancer (BC). In this study, we aim to determine 
differentially-expressed miRNAs utilising primary BCs that did not relapse (BCNR, n = 12), primaries 
that relapsed (BCR) and their paired (n = 40 pairs) brain metastases (BM) using the NanoString™ 
nCounter™ miRNA Expression Assays. Significance analysis of microarrays identified 58 and 11 
differentially-expressed miRNAs between BCNR vs BCR and BCR vs BM respectively and pathway 
analysis revealed enrichment for genes involved in invasion and metastasis. Four miRNAs, miR-132-3p, 
miR-199a-5p, miR-150-5p and miR-155-5p, were differentially-expressed within both cohorts (BCNR-
BCR, BCR-BM) and receiver-operating characteristic curve analysis (p = 0.00137) and Kaplan-Meier 
survival method (p = 0.0029, brain metastasis-free survival; p = 0.0007, overall survival) demonstrated 
their potential use as prognostic markers. Ingenuity pathway enrichment linked them to the MET 
oncogene, and the cMET protein was overexpressed in the BCR (p < 0.0001) and BM (p = 0.0008) 
cases, compared to the BCNRs. The 4-miRNAs panel identified in this study could be potentially used 
to distinguish BC patients with an increased risk of developing BCBM and provide potential novel 
therapeutic targets, whereas cMET-targeting warrants further investigation in the treatment of BCBM.
Despite the improvements in the treatment of breast cancer (BC), recurrence and metastasis remain a major clini-
cal problem. Breast cancer brain metastases (BCBM) are a growing clinical problem, and an area of unmet clinical 
need1,2. During the invasive-metastatic cascade, malignant cells must develop stem-cell characteristics, evade the 
immune system and adapt to the different microenvironments through which they pass in order to metastasise 
and seed in the target organ3,4. MicroRNAs (miRNAs), may interact with numerous mRNAs and differentially 
modulate their expression and the corresponding protein levels in a tissue and cell type-specific manner5. In the 
context of cancer, miRNAs are known to regulate a number of disease-related protein-coding genes, having there-
fore, diagnostic and prognostic potential, as well as being potential therapeutic targets3,5–9.
Several studies using BC cell lines, mouse models and primary or advanced BC clinical samples have identi-
fied miRNAs linked to the metastatic process3,5–10. For instance, higher levels of miRNA-10b in the primary BC 
correlated with concurrent BCBM, with in-vitro and in-vivo data demonstrating that miRNA-10b promotes inva-
sion by inhibition of HOXD10, which in turn de-represses the expression of the pro-metastatic RhoC gene6,8,10,11. 
MiRNA-21 is another BC-related miRNA that promotes in-vitro and in-vivo tumour growth by targeting PTEN 
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and TPM1 tumour-suppressor genes, whereas it affects metastasis by directly targeting TIMP3, SERPIN5B, 
PDCD4 and BCL28,9.
To date, only three studies with very limited numbers of samples (n = 4–9), have compared miRNA expression 
between matched primary unselected BC and BCBM tissues12–14. The current study screened a larger cohort of 
unselected BC samples that recur (BCR) and their paired brain metastases (BM), as well as primary BC samples 
that did not recur (BCNR) to identify differentially-expressed miRNAs related to BCBM. Such information is 
vital if biomarkers or therapeutic targets are to be identified which could transform the prevention and treatment 
of BCBM.
Results
Patient characteristics. A total of 12 BCNR and 40 BCR patients who developed BM were included in 
the study. Among the primary BCNR cohort, 9 (75%) were ER+ and 3 (25%) were HER2+, whereas in the BCR 
cohort, 21 (52.5%) were ER+, 11 (27.5%) were HER2+ and 8 (20%) were triple negative (TNs). The distribution 
of the subtypes changed in the BM setting with the majority of ER+ primary BCRs losing their ER status; 10/21 
(47.6%) ER+ and 3/5 (60%) HER2+/ER+ lost ER expression. The data is summarised in Table 1.
Differentially expressed miRNAs between primary BCNR vs BCR and BCR vs BCBMs. 
Assessment of the global variation using principal component analysis (PCA) applied to the miRNA counts indi-
cated a molecular distinction between the primary BCNR (blue dots), the BCRs (red dots) that progress to brain 
metastasis and the BCBM (green dots) cases, with a small number of overlapping samples mainly between BCRs 
and BCBMs (Fig. 1A).
Significance analysis of microarrays (SAM) identified 116 differentially-expressed miRNAs between primary 
BCNRs and BCRs with 10% false discovery rate (FDR) (Supplementary Table 1), 58 of which (31 downreg-
ulated and 27 upregulated miRNAs in BCR versus BCNR) had absolute log2 fold-changes (FC) > 1 (Fig. 1B, 
Supplementary Table 1: dark and light-grey respectively). Pathway clustering (DIANA-mirPath_v3.0) revealed 
enrichment for genes involved in extracellular matrix (ECM)-receptor interactions, proteoglycans, p53, TGF-β, 
hippo and FOXO signalling, fatty acid biosynthesis/degradation/metabolism, adherens junctions and cell cycle 
(Fig. 1C,D, Supplementary Fig. 1A,B). Core ingenuity pathway analysis (IPA) identified a network of genes impli-
cated in proliferation of immune cells, migration and metastasis, directly and/or indirectly regulated by the iden-
tified miRNA signature (Supplementary Fig. 2A–D).
Comparison of the primary BCRs and their paired BMs by SAM revealed 112 differentially-expressed miR-
NAs with 10% FDR (Supplementary Table 2), 11 of which (9 upregulated and 2 downregulated in BCR ver-
sus their paired BMs) had log2 FC > 1 (Fig. 2A, Supplementary Table 2: light and dark-grey respectively). The 
11 miRNAs are highly enriched for genes involved in ECM-receptor interactions, proteoglycans, adherens 
junctions, p53, TGF-β, hippo signalling, fatty acid biosynthesis/degradation/metabolism and focal adhesion 
(DIANA-mirPath_v3.0) (Fig. 2B,C, Supplementary Fig. 3A,B). IPA core analysis identified a network of genes 
implicated in proliferation of immune cells, metastasis and colonisation, directly and/or indirectly regulated by 
the identified miRNA signature (Supplementary Fig. 4A–D).
A signature of miRNAs may define distant metastasis to the brain. Four of the significantly 
differentially-expressed miRNAs identified by SAM, hsa-miR-132-3p, hsa-miR-199a-5p, hsa-miR-150-5p and 
hsa-miR-155-5p were present within both cohorts of BCNR vs BCR and BCR vs BCBM (Fig. 3A). Statistical 
analysis (t-test) on the individual miRNAs showed a p < 0.01 and p < 0.0001 for all these miRNAs between 
BCNR vs BCR and BCR vs BCBM respectively (Fig. 3A). Only the hsa-miR-199a-5p showed a significant p 
value (p < 0.0001) between BCNR and BCBM. The differential expression of the 4 miRNAs within BCNR vs 
BCR (irrespectively of BC subtype) and BCR vs BCBM cohorts leads us to focus and investigate them further. 
In order to discriminate BCNR from BCR and study the diagnostic accuracy of these miRNAs as biomarkers 
for brain metastasis, receiver-operating characteristic curve (ROC) analysis was performed (Fig. 3B) using their 
mean log2-expression values. The area under the curve (AUC) was 0.8194 (95% CI: 0.6932–0.9457, p = 0.00137), 
meaning that a patient (BCR) will have a more abnormal test result than 81.94% of the controls (BCNR). The 
cut-off level of the combined 4-miRNA was 7.892 with 76.7% sensitivity and 83.3% specificity. This cut-off was 
used to dichotomised the primary BC cases into high-risk (>7.892) and low-risk (<7.892) and was used to 
perform Kaplan-Meier (log-rank) analysis of BMFS and OS. The result showed that low-risk group had a higher 
BMFS rate (p = 0.0029, HR: 0.314, 95% CI: 0.146–0.673) and a better overall survival (p = 0.0007, HR: 0.267, 
95% CI: 0.124–0.573) than the high-risk group (Fig. 3C,D respectively), confirming that the expression levels of 
the 4-miRNA signature were significantly correlated with patient outcome. The individual miRNA contribution 
in BMFS and OS is illustrated in Supplementary Fig. 5. High miR-132-3p expression confers a protective effect 
whereas high miR-150-5p, miR-155-5p and miR-199a-5p confer a risky effect (HR < 1 and HR > 1 respectively).
IPA’s miRNA target-filter functionality with filtering for experimentally validated targets identified 147 
genes linked to 4 major networks (Fig. 4A). MET (cMET, HGF human growth factor ligand) oncogene was 
one of the genes in the top identified network (ID1, Fig. 4A) and it was also present in the IPA core analysis 
of the differentially-expressed miRNAs between BCNR vs BCR (Supplementary Fig. 2A) and BCR vs BCBM 
(Supplementary Fig. 4A). The cMET was overexpressed in primary BCRs and their paired BMs in comparison 
to the primary BCNRs (Fig. 4B: BCNR vs BCR: p < 0.0001 and BCNR vs BCBM: p = 0.0008), indicating an acti-
vation of the HGF/cMET pathway in the BCs that relapse and in BM. Representative examples of cMET staining 
of two primary breast cancer cases without recurrence (BCNR) and 2 primary BCRs with their matched brain 
metastasis are illustrated in Fig. 4C.
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Discussion
In this study, we investigated the differential-expression of miRNAs between primary BCNR vs primary BCR and 
primary BCR vs their paired BMs. Assessment of the global variation using PCA indicated a molecular distinc-
tion between the primary BCNR, the BCRs that progress to brain metastasis and the BCBM cases. The overlap 
observed between the primary BCRs and their paired BMs suggests that many of the miRNAs linked to metas-
tasis are already present in a proportion of the matched primary breast tumours. Consistent with the literature, 
we observed hormone (ER and/or PgR) receptor loss in BCBM cases15–17. Since brain metastasis is a late event 
in hormone receptor-positive BC, cases losing hormone sensitivity may behave more like TNs that are known to 
have a higher rate of BM and a worse prognosis.
Comparison of the primary BC samples that do not relapse with the ones that relapse, revealed 58 
differentially-expressed miRNAs, many of which have been previously shown to be involved in breast tumouri-
Patient No Status
ER status 
of the 
1oBC
ER 
status of 
BM
PgR 
status of 
the 1oBC
PgR 
status of 
BM
HER2 
status of 
the 1oBC
HER2 
status of 
BM
Time (months) 
between breast-
brain surgeries/
recurrence
Time (months) 
between breast 
surgery and 
death
119 ER+ + + − + − − 62 85
560 ER+/PgR+ + + + + − − 97 103
666 ER+/PgR+ + − + − − − 38 55
690 ER+/PgR+ + + + + − − 44 72
707 HER2+/ER+ + − − − + + 48 89
712 ER+ + − − − − − 28 32
725 ER+/PgR+ + − + + − − 22 26
756 HER2+/ER+ + − − − + +* 25 53
827 TN − − − + − − 16 NA
912 ER+/PgR+ + + + + − − 60 94
943 TN − − − − − − 36 61
972 HER2+/HR+ + − + + + + 27 29
1004 ER+ + − − + − − 10 NA
1020 TN − − − + − − 26 NA
1148 ER+/PgR+ + + + + − − 51 52
1386 ER+ + − − − − − 11 NA
1662 ER+ + − − + − − 39 54
1709 TN − − − + − − 23 25
12051 ER+ + − − − − − 6 29
12321 ER+ + − − − − − 14 64
12372 HER2+ − NA − NA + NA 14 25
12364 HER2+ − − − − + + 29 64
13147 ER+/PgR+ + − + − − − 24 42
13263 ER+ + + − − − − 30 42
13630 TN − − − − − − 30 31
13631 HER2+ − − − NA + +* 21 30
13692 TN − − − NA − − 35 44
14063 TN − − − NA − − 26 31
14222 ER+/PgR+ + + + + − − Synchronous 50
15311 ER+/PgR+ + + + + − − NA 174
RCSI_1 HER2+ − − − − + + 20 31
RCSI_2 HER2+/ER+ + + − − + + 37 104
RCSI_3 HER2+ − − − − + + 67 115
RCSI_5 ER+ + + − − − + 53 74
RCSI_6 TN − − − − − − 23 40
RCSI_7 ER+ + + − − − + 53 73
RCSI_8 ER+ + + − − − − 59 97
RCSI_9 HER2+ − − − − + + 17 40
RCSI_10 HER2+ − − − − + + 70 112
RCSI_11 ER+ + − − − − − 8 17
Table 1. Hormone receptor (ER and PgR) and HER2 status of the primary BCR and their matched BCBM 
cases. The table indicates the differences of the ER, PgR and HER2 status between the primary BCR and BCBM 
cases. Samples were collected from Walton Tissue Bank, Liverpool, UK and Royal College of Surgeons Ireland 
(RCSI) National Breast Cancer Bioresource, Ireland. NA: Not available,+: positive, −: negative. *2+, FISH not 
available.
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Figure 1. Principal component analysis and miRNA expression profiling of primary breast cancer (BC) without 
recurrence and primary BC that recurs to the brain. (A) Principal component analysis (PCA) of the miRNA 
expression values after sample and array normalisation. PC1 (horizontal axis) accounted for 16.1%, while PC2 
(vertical axis) accounted for 12.5% of the observed variation. The blue spots represented the primary BCs that 
did not recur (BCNR), whereas the red and green spots represented the primary BC that recurred in the brain 
(BCR) and BCBM samples respectively. There is an observed shift from the BCNR to BCR and from BCR to 
BCBM highlighting the molecular distinction. (B) Significant analysis of microarrays (SAM) with 10% false 
discovery rate (FDR) and fold-change (FC) > 2 separates the primary BCNR (NM in the dendrogram) from the 
primary BCRs (BC and RSCI_BC in the dendrogram). 31 miRNAs were downregulated (green) and 27 were 
upregulated (red) in BCRs in comparison to the BCNRs. Pathway enrichment analysis (DIANA-mirPath v3.0) 
of the (C) 31 downregulated and (D) 27 upregulated miRNAs in BCRs in comparison to the BCNRs with the 
top significant KEGG pathways plotted.
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genesis, progression and metastasis targeting a number of key oncogenes or tumour-suppressor genes6–10,14,18,19. 
Inflammation and immunity have been also shown to contribute to the development and progression of BC and a 
number of the identified miRNAs including miR-150, miR-155, miR-146, miR-130/301 and the miR-17/92 clus-
ter are involved in regulating genes and pathways in these processes3,20–27. IPA linked them to interleukins (IL), 
toll-like receptors (TLR) and C-reactive protein (CRP), whereas miRNA target-filter analysis linked them to ILs, 
TLR, Th1/Th2 and neuro-inflammation signalling pathways; (Supplementary Fig. 6A) highlighting the activation 
of an inflammatory network involved in the metastatic process.
To identify miRNAs that may be associated with BCBM, we analysed a cohort of primary BCs that recur and 
their paired BMs. This revealed a signature of 11 differentially-expressed miRNAs with previously published 
in-vitro and in-vivo data supporting their relevance in the processes of invasion and metastasis8–12,14,24,28,29. For 
instance, higher expression of miR-155-5p has been reported in localised early breast cancer than in metastasis, 
including brain metastasis28. The miR-155-5p promotes cancer cell extravasation by regulating the function of 
the blood-brain endothelial barrier and its overexpression shifts the TGF-β response from growth inhibition to 
EMT transition, invasion and metastasis in breast cancer through loss of C/EBP-β3,8,23,24. Moreover, miR-199a-3p 
Figure 2. miRNA expression profiling and pathway enrichment analysis of the primary breast cancer (BCR) 
and their paired breast cancer brain metastasis (BCBM). (A) Significant analysis of microarrays (SAM) with 
10% false discovery rate (FDR) and fold-change (FC) > 2 distinguishes the primary BCR (BC, RSCI_BC 
in the dendrogram) from their paired BCBM (BCBM, RSCI_BCBM in the dendrogram). 2 miRNAs were 
downregulated (green) and 9 were upregulated (red) in BCRs in comparison to the BCBMs. Pathway 
enrichment analysis (DIANA-mirPath v3.0) of the (B) 2 downregulated and (C) 9 upregulated miRNAs in BCRs 
in comparison to the BCNRs with the top significant KEGG pathways plotted.
6Scientific RepoRtS |         (2019) 9:18518  | https://doi.org/10.1038/s41598-019-55084-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
and miR-214-3p, both up-regulated in human BC stem cells, enhance stem cell behaviour and facilitate metastasis 
by targeting Ezh2, p53, PTEN, BIM, and Snail8,26,30. Within our current cohort of primary BCs and their paired 
BMs, miR-10b-5p, miR-150-5p were upregulated while, miR-132-3p, and miR-9-5p were downregulated. These 
miRNAs have been linked to the induction of mesenchymal markers early in the EMT transition and to neovas-
cularisation, both facilitating metastatic growth3,8–10,31. Overexpression of miR-150 promotes growth, clonogenic-
ity and reduces apoptosis in breast cancer cells29,32, whereas primary BCs with increased levels of miRNA-10b 
have been associated with lymph node metastasis, de novo metastatic disease, as well as brain metastasis3,6,8–11. 
Consistent with our data, miR-9 has been reported to be upregulated in non-CNS metastatic disease when com-
pared to the primary BC, supporting its role in metastasis and colonisation14. In comparison to normal tissue, 
miR-132-3p is downregulated in primary BC, whereas its overexpression in cell lines and animal models, sig-
nificantly suppress BC cell proliferation, invasion, migration and metastasis33–35. Interestingly, miR-132-3p has 
been characterised as a ‘neuro-immunomiR’, a class of miRNAs which operate within and between the neural and 
immune compartments supporting its potential importance in brain metastasis36. A recent study showed that 
over-expression of miR-212/132 in hypoxic mouse and human brain microvascular endothelial cells decreased 
the blood-brain-barrier properties by targeting the transcription of tight junction and tight junction-associated 
proteins, highlighting further the importance of this miRNA in the brain37. MiR-132, miR-155, miR-150 and 
miR-10b regulate both innate and adaptive immunity and in the context of cancer, their immunomodulatory 
effects can enable malignant cells to evade the immune system21–23,25,38. The 11 differentially-expressed miR-
NAs within the primary BCR and their paired BMs were also linked by IPA to genes and pathways involved in 
inflammation and immunity, cell stemness and EMT transition. IPA target-filter analysis linked them to ILs, 
PI3K and neuroinflammation signalling pathways (Supplementary Fig. 6B), highlighting further the activation of 
an inflammatory network. The current data demonstrate the potential importance of immuno-regulation in the 
biology of BCBM and the potential for the use of immuno-oncology agents in their treatment39,40.
Four of the differentially-expressed miRNAs within the primary BCRs and their paired BMs, miR-132-3p, 
miR-150-5p, miR-199a-5p, miR-155-5p, were also differentially-expressed in the cohort of primary BCNRs as 
compared to primary BCRs. This observation lead us to focus and investigate them further. To evaluate their 
prognostic significance, we calculated the AUC of the ROC curve for development of brain metastasis using the 
BCNR patients as non-metastatic controls. The high AUC value indicated that the 4-miRNAs can distinguish a 
Figure 3. Prognostic potential of the 4-miRNA signature. (A) T-test (Welch’s correction) was used to compare 
the primary BCNR with BCRs and Wilcoxon signed-rank test (Gaussian approximation) was used to compare 
the BCR and their paired BCBMs. *Only hsa-miR-199a-5p showed a significant difference (p < 0.0001) in 
expression between BCNR and BCBM. (B) Receiver-operating characteristic (ROC) curve analyses of the 
mean log2 expression of the four-miRNA signature was used to discriminate BCNR (control group) from BCR 
(metastasis group). The identified area under the curve (AUC = 0.8194) supports the prognostic potential 
of this 4-miRNA signature. (C,D) Kaplan-Meier survival analysis showed that low-risk patients had a better 
brain metastasis-free survival (C) and overall survival (D) than the high-risk with p = 0.0029 and p = 0.0007 
respectively.
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Figure 4. Ingenuity pathway network analysis of the genes targeted by the 4 differentially-expressed miRNAs 
and cMET immunohistochemistry of primary breast cancer that did not recur (BCNR), primary BCR and 
breast cancer brain metastasis (BCBM). (A) IPA of the 147 genes targeted enrichment analysis linked them 
to 4 major networks (ID1-4), the top identified network (ID 1) is illustrated with the highest score and focus 
molecules. MET (cMET) oncogene was one of the genes in this network (B) cMET IHC using the H-score as a 
semi-quantitative measure for the t-test analysis identified a significant overexpression of cMET in BCRs and in 
BCBMs (p < 0.0001: BCNR vs BCR and p = 0.0008: BCNR vs BCBM). (C) Representative examples stained for 
cMET of 2 primary breast cancer cases without recurrence (BCNR1 and BCNR2) and 2 primary BCR with their 
matched brain metastasis (BCR1 and BM1, BCR2 and BM2).
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patient that will relapse to the brain from the one who will not, supporting the prognostic potential of the identi-
fied 4-miRNAs signature. Further to the ROC curve analysis, Kaplan-Meier survival plot showed that the low-risk 
group had a 60% brain metastasis-free survival rate and 67% OS, whereas the high-risk group had metastasis-free 
and overall survival rate lower than 10%.
Of interest, the oncogene MET, encoding the transmembrane receptor cMET, was common in all the IPA 
network analyses. In BC, cMET is associated with aggressive clinico-pathological features, shorter disease-free/
overall survival and brain metastasis41–43. Consistent with these data, we observed cMET overexpression in BCR 
and their paired BMs but not in the BCNR samples. Previously, we also demonstrated increased cMET copy num-
ber in paired primary BCR and their BMs44. The above, highlight an active cMET pathway in primary BC samples 
that recurred to the brain as well as in BCBM but not in primary BC cases that do not recur.
Microglial cells are known to express cMET and produce HGF, contributing to angiogenesis of brain 
tumours42,45,46. A paracrine cytokine loop present between tumour-associated astrocytes and cancer cells results 
in continuous activation of the cMET pathway leading to induction of angiogenesis42. Therefore, cMET appears 
able to promote brain colonisation and maintenance via promoting angiogenesis within the CNS. Silencing cMET 
in combination with radiotherapy in a brain metastatic mouse model significantly prolonged survival, demon-
strating its therapeutic potential47. cMET activation is also know to modulate immune cell functions, therefore, 
inhibition of cMET signalling may not only suppress cancer cell growth but also stimulate the immune system by 
alleviating the immunosuppressive effects on macrophages and dendritic cells45,46,48. Given that there are avail-
able drugs targeting cMET, the potential benefit of targeting cMET-positive BCBM with these agents warrants 
investigation.
A limitation of our study is the challenge in collecting a larger number of matched primary BC and BM cases. 
Moreover, it had been previously observed that the miRNA levels gradually decreased over time in long-archived 
FFPE blocks49 and this accounted for the limited number of BCNR cases with a long follow-up available in 
our study. Therefore, an analysis by subtypes was not feasible. In an attempt to reduce the possible effect of the 
TN cases (absent in our BCNR cohort) we further analysed the BCNR vs ER + /HER2 + BCR (Supplementary 
Table 3). Of the 4 miRNAs, miR-132-3p, miR-150-5p, miR-199a-5p and miR-155-5p, only miR-155-5p was absent 
in the combined BCNR vs ER + /HER2 + BCR analysis indicating that its expression may be more relevant to 
TNBC23,28. However, given the hormone loss in the metastatic setting and the previous report of miR-155-5p 
in brain metastasis, we believe that this miRNA is still important and its role requires further investigation. In 
addition, the majority of patients with metastatic breast cancer, might present metastases to other organs such as 
bones, liver, lungs prior to the development of BM. However, the presence of BM regardless of other metastatic 
sites is a critical clinical complication, conferring a dismal prognosis to the patients. The patients included in 
this study came from the biobank of a specialist tertiary referral neurosurgical centre (Walton Hospital) and 
the relevant detailed clinical information with regard to other involved anatomical sites was not collected by the 
biobank. Given the samples are anonymised we were unable to seek out and collect this information. Finally, the 
patients included in this study may have received some form of systemic therapy and/or radiotherapy prior to 
the biopsy of the metastatic lesion. Therefore, the detected miRNAs might be affected by the metastatic process, 
the therapy or a combination of both. Despite these limitations, this study provides a comprehensive analysis of 
differentially-expressed miRNAs in primary BCs that did not relapsed versus primary BCs that relapsed to the 
brain and their matched brain metastasis. It should be also noted, that the current study represents the largest set 
of unselected matched primary breast tumours and brain metastases so far.
In summary, this is the first study to report a panel of differentially-expressed miRNAs in BCBM that could 
potentially be used to identify BC patients at increased risk of BCBM as well as provide potential novel thera-
peutic targets. Since these miRNAs were also linked to cMET using network analysis, the data supports a novel 
therapeutic strategy for BCBM that is focused on targeting cMET.
Methods
Patients. A total of 12 formalin-fixed paraffin-embedded (FFPE) primary BCNR and 40 primary BCR sam-
ples with their paired BMs were collected from the Liverpool Tissue Bank, Walton Research Tissue Bank (WRTB) 
Liverpool, UK and the Royal College of Surgeons Ireland (RCSI) National Breast Cancer Bioresource, Ireland. The 
specimens were reviewed by two pathologists (SR,KB) and defined as per local protocol. Briefly, ER, PgR positiv-
ity was defined using the Allred scoring system (3–8), whereas HER2 status was classified as negative (staining 
0–1), positive (staining 3 + ). Amplification of HER2 was confirmed by FISH (fluorescent in-situ hybridisation) 
if the staining was 2 + (equivocal). The cMET protein expression was assessed by immunohistochemistry (IHC). 
Intensity was scored according to a four-tier systems: 0, no staining; 1+, weak; 2+, moderate; and 3+, strong. The 
H-score was used as a semi-quantitative measure by multiplying the staining intensity (0–3) and the percentage of 
positive cells (0–100%) for a final IHC score ranging from 0 to 300. The study was performed in accordance with 
the Declaration of Helsinki and approved by the WRTB Ethics committee (WRTB15_06), the National Research 
Ethics Committee (NRES 11/WN003/2), the UK Health Research Authority (NRES 12/NW/0778) and the RCSI 
Institutional Review Board (#13/09; ICORG09/07). Appropriate approvals and written consent were in place 
before anonymised tissue and data were released.
RNA extraction and miRNA profiling. RNA was extracted using the miRNeasy FFPE kit (Qiagen, 
Manchester, UK) and quantified on the ND-Nanodrop1000 spectrometer (ThermoFisher Scientific, Wilmington, 
MA, USA). RNA integrity number (RIN) was determined using the 2100 Agilent Bioanalyzer (Agilent 
Technologies, Palo Alto, CA). Profiling was performed using the NanoString™ nCounter™ miRNA Expression 
Assay (Human_v3 miRNA) according to the manufacturer’s instructions. The raw data were quality control (QC) 
assessed and normalised by the NanoString™ nSolver™ analysis software. Fifteen cases (5 paired BCR-BM, 2 
BCRs and 3 BMs) failed the NanoString™ QC and normalisation and were excluded from downstream analysis 
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together with their matched samples. MiRNAs with median expression lower than the upper quartile of the 
in-built negative controls were removed and an additional quantile normalisation procedure (R-Bioconductor) 
was applied to remove technical variation between different arrays resulting in a final dataset containing 166 miR-
NAs (Supplementary File 1). Principle component analysis (PCA) of the normalised log2-transformed data was 
done using the prcomp function within the R software for statistical analysis. Significance analysis of microarrays 
(SAM) was performed on the Multi-Experiment viewer (MeV) 4.9 software to identify differentially-expressed 
miRNAs between BCNR vs BCR and BCR vs their paired BM50.
Pathway analysis. Pathway analysis was carried out using DIANA-mirPath_v3.0 a web-server, utilizing 
the DIANA-microT-CDS algorithm, the DIANA-TarBase and the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways51. Fisher’s Exact test (hypergeometric distribution) corrected for multiple testing with p < 0.05 
threshold was used to define pathway enrichment. Ingenuity Pathway Analysis (IPA, Qiagen bioinformatics) was 
used for network and miRNA gene-target enrichment analysis.
Statistical analysis. Two sample unpaired t-test (Welch’s correction) was used to compare the primary 
BCNR with the BCRs and Wilcoxon signed-rank paired t-test (Gaussian approximation) was used to compare the 
BCR and their paired BMs. Receiver-operating characteristic (ROC) curve analysis of the mean log2 expression of 
the four-miRNAs signature was used to discriminate BCNR (control) from BCR (cases) patients and evaluate the 
diagnostic accuracy of the selected miRNAs. The median patient follow-up of the BCNR controls was 17 years. 
Kaplan-Meier (Log-rank) survival analysis was used to determine the brain metastasis-free survival (BMFS: time 
between breast-brain surgeries/recurrence) and overall survival (OS: time between breast surgery to death). All 
the statistical analysis was performed on GraphPad Prism v5 software (GraphPad Inc, San Diego, USA).
Ethics approval and consent to participate. This project was peer reviewed by the Walton Research 
Tissue Bank (WRTB15_06), an approved repository under the Human Tissue Act (National Research Ethics 
Service: NRES 11/WN003/2), the UK Health Research Authority (NRES 12/NW/0778) and the RCSI 
Institutional Review Board (#13/09; ICORG09/07). Appropriate approvals and written consent were in place 
before anonymised tissue and data were released. The study was performed in accordance with the Declaration 
of Helsinki.
Data availability
All the data (raw counts and normalised counts) analysed in this study are available in the Additional File 1 
(Additional file 1_Raw Counts and Normalised Data.xlsx) submitted with the manuscript.
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